Alpha Cognition Inc (ACOG) - Net Assets
Based on the latest financial reports, Alpha Cognition Inc (ACOG) has net assets worth $33.91 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($46.30 Million) and total liabilities ($12.39 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Alpha Cognition Inc tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $33.91 Million |
| % of Total Assets | 73.25% |
| Annual Growth Rate | 613.4% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 28210.68 |
Alpha Cognition Inc - Net Assets Trend (2020–2024)
This chart illustrates how Alpha Cognition Inc's net assets have evolved over time, based on quarterly financial data. See ACOG defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Alpha Cognition Inc (2020–2024)
The table below shows the annual net assets of Alpha Cognition Inc from 2020 to 2024. For live valuation and market cap data, see Alpha Cognition Inc (ACOG) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $41.46 Million | +979.83% |
| 2023-12-31 | $-4.71 Million | -256.97% |
| 2022-12-31 | $-1.32 Million | -114.62% |
| 2021-12-31 | $9.03 Million | +56306.74% |
| 2020-12-31 | $16.01K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alpha Cognition Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5779615100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $99.13 Million | 239.08% |
| Other Comprehensive Income | $-104.30K | -0.25% |
| Other Components | $18.72 Million | 45.16% |
| Total Equity | $41.46 Million | 100.00% |
Alpha Cognition Inc Competitors by Market Cap
The table below lists competitors of Alpha Cognition Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Waterco Ltd
AU:WAT
|
$127.20 Million |
|
Jalles Machado S/A
SA:JALL3
|
$127.21 Million |
|
Paxman AB
ST:PAX
|
$127.23 Million |
|
Lake Shore Bancorp Inc
NASDAQ:LSBK
|
$127.38 Million |
|
Humanica Public Company Limited
BK:HUMAN
|
$127.19 Million |
|
Siam Wellness Group Public Company Limited
BK:SPA
|
$127.12 Million |
|
Energy World Corporation Ltd
AU:EWC
|
$127.11 Million |
|
SciVision Biotech Inc
TW:1786
|
$127.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alpha Cognition Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -4,712,604 to 41,463,045, a change of 46,175,649.
- Net loss of 14,636,865 reduced equity.
- New share issuances of 56,541,384 increased equity.
- Other comprehensive income decreased equity by 8,391,152.
- Other factors increased equity by 12,662,282.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-14.64 Million | -35.3% |
| Share Issuances | $56.54 Million | +136.37% |
| Other Comprehensive Income | $-8.39 Million | -20.24% |
| Other Changes | $12.66 Million | +30.54% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Alpha Cognition Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.17x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 865.36x to 1.17x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.01 | $6.68 | x |
| 2021-12-31 | $4.23 | $6.68 | x |
| 2022-12-31 | $-0.49 | $6.68 | x |
| 2023-12-31 | $-1.31 | $6.68 | x |
| 2024-12-31 | $5.72 | $6.68 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alpha Cognition Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.22x
- Recent ROE (-35.30%) is above the historical average (-7277.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -36133.23% | 0.00% | 0.00x | 527.00x | $-5.79 Million |
| 2021 | -216.46% | 0.00% | 0.00x | 1.43x | $-20.45 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.98 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-13.30 Million |
| 2024 | -35.30% | 0.00% | 0.00x | 1.22x | $-18.78 Million |
Industry Comparison
This section compares Alpha Cognition Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alpha Cognition Inc (ACOG) | $33.91 Million | -36133.23% | 0.37x | $127.19 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Alpha Cognition Inc
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatm… Read more